Article

Cefuroxime combats endophthalmitis

It is possible to achieve a lower rate of endophthalmitis with a single injection of cefuroxime at the conclusion of cataract surgery than by using the more traditional subconjunctival/topical regimens, according to Per Montan of the St Erik Eye Hospital, Stockholm, Sweden.

It is possible to achieve a lower rate of endophthalmitis with a single injection of cefuroxime at the conclusion of cataract surgery than by using the more traditional subconjunctival/topical regimens, according to Per Montan of the St Erik Eye Hospital, Stockholm, Sweden.

In 1996, St Erik's analysed the resistance patterns of 55 causative bacteria and found that 51 of these were sensitive to cefuroxime, a second-generation cephalosporin. It was decided to use 1 mg cefuroxime as a bolus injection at the conclusion of cataract extraction. A sharp decline in endophthalmitis was soon noticed and furthermore, the antibiotic proved to be safe in analyses of endothelial cell counts, laser flare measurements and the presence of IgE production.

Nationwide data confirmed these findings and now, 99% of cataract procedures are performed with intracameral cefuroxime. The incidence of endophthalmitis during the period between 2002 and 2004, based on a sample of 224,000 operations, is just 0.04%. For comparison purposes, data collected between 1999 and 2001, showed that, of the 6,800 procedures performed using topical or subconjunctival antibiotics, the incidence of endophthalmitis was 0.22% compared with 0.05% in the 153,000 operations using cefuroxime.

Montan concluded that it is entirely possible to achieve significantly lower rates of endophthalmitis by using cefuroxime than by using more traditional combined regimens.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.